RA CAPITAL MANAGEMENT, L.P.

Average Profitability
<0.0001%
Insider Buys Quantity
127
Insider Buys Sum
$1.62B
Insider Sells Quantity
70
Insider Sells Sum
$211.17M

Insider Activity of RA CAPITAL MANAGEMENT, L.P.

According to the SEC Form 4 filings, RA CAPITAL MANAGEMENT, L.P., being in a position of

  1. at 89bio, Inc.,
    оver the last 12 months, has bought 1350000 shares for $20.72M, and sold 0 shares,
    over all time since 2019-11-11, has bought 11593389 shares for $214.16M, and sold 0 shares.

The largest purchase of all time was on 2020-07-14 and amounted to 6666666 shares of Nkarta, Inc. for $120M.

The largest sale of all time was on 2021-03-11 and amounted to 710000 shares of Phathom Pharmaceuticals, Inc. for $31.06M.

Biography of RA CAPITAL MANAGEMENT, L.P.

No biography is available at this moment.

2024-10-18PurchaseJanux Therapeutics, Inc.
JANX
1.2M
2.0576%
$44.75$53.7M+8.53%
2024-09-16PurchaseBicara Therapeutics Inc. Common Stock
BCAX
1.83M
2.6517%
$18.00$32.99M-6.73%
2024-06-17PurchaseAerovate Therapeutics, Inc.
AVTE
928,110
0.2418%
$1.67$1.55M+15.15%
2024-03-27PurchaseNkarta, Inc.
NKTX
3M
5.4767%
$10.00$30M-43.62%
2024-03-04Purchase89bio, Inc.
ETNB
1.35M
1.6718%
$15.35$20.72M-36.79%
2024-02-09PurchasePepGen Inc.
PEPG
2.56M
10.4935%
$10.64$27.21M-9.75%
2024-01-11PurchaseSolid Biosciences Inc.
SLDB
904,160
3.235%
$5.53$5M+8.09%
2023-12-11PurchaseWave Life Sciences Ltd.
WVE
1M
1.2134%
$5.00$5M+37.89%
2023-07-21PurchaseAcumen Pharmaceuticals, Inc.
ABOS
5.16M
13.1759%
$7.75$40M-51.62%
2023-07-19PurchaseJanux Therapeutics, Inc.
JANX
495,008
1.1638%
$12.46$6.17M-13.24%
2023-07-05PurchaseBlack Diamond Therapeutics, Inc.
BDTX
director
935,850
2.639%
$5.00$4.68M-26.34%
2023-03-24Purchase89bio, Inc.
ETNB
2.46M
4.6238%
$16.25$40M-7.38%
2023-01-20PurchaseFulcrum Therapeutics, Inc.
FULC
director
1.92M
3.8009%
$13.00$25M-68.65%
2023-01-06PurchaseWerewolf Therapeutics, Inc.
HOWL
director
1.85M
5.9218%
$2.21$4.1M+17.33%
2023-01-04PurchaseFulcrum Therapeutics, Inc.
FULC
director
180,703
0.3049%
$7.28$1.31M-52.11%
2022-12-27PurchaseFulcrum Therapeutics, Inc.
FULC
director
4,089
0.009%
$5.99$24,510-34.35%
2022-12-19PurchaseFulcrum Therapeutics, Inc.
FULC
director
98,787
0.2145%
$5.90$582,814-34.35%
2022-12-16PurchaseFulcrum Therapeutics, Inc.
FULC
director
1.34M
3.0203%
$5.42$7.27M-25.98%
2022-12-15PurchaseFulcrum Therapeutics, Inc.
FULC
director
237,029
0.5283%
$5.50$1.3M-27.65%
2022-12-14PurchaseFulcrum Therapeutics, Inc.
FULC
director
824,600
1.8392%
$5.46$4.5M-27.11%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.